Hide metadata

dc.contributor.authorBrkic, Alen
dc.contributor.authorDiamantopoulos, Andreas P.
dc.contributor.authorHaavardsholm, Espen A.
dc.contributor.authorFevang, Bjørg T. S.
dc.contributor.authorBrekke, Lene K.
dc.contributor.authorLoli, Liz
dc.contributor.authorZettel, Camilla
dc.contributor.authorRødevand, Erik
dc.contributor.authorBakland, Gunnstein
dc.contributor.authorMielnik, Pawel
dc.contributor.authorHaugeberg, Glenn
dc.date.accessioned2022-01-11T06:03:17Z
dc.date.available2022-01-11T06:03:17Z
dc.date.issued2022
dc.identifier.citationBMC Health Services Research. 2022 Jan 10;22(1):48
dc.identifier.urihttp://hdl.handle.net/10852/89915
dc.description.abstractBackground In Norway, an annual tender system for the prescription of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) has been used since 2007. This study aimed to explore annual b/tsDMARDs costs and disease outcomes in Norwegian rheumatoid arthritis (RA) patients between 2010 and 2019 under the influence of the tender system. Methods RA patients monitored in ordinary clinical practice were recruited from 10 Norwegian centers. Data files from each center for each year were collected to explore demographics, disease outcomes, and the prescribed treatment. The cost of b/tsDMARDs was calculated based on the drug price given in the annual tender process. Results The number of registered RA patients increased from 4909 in 2010 to 9335 in 2019. The percentage of patients receiving a b/tsDMARD was 39% in 2010 and 45% in 2019. The proportion of b/tsDMARDs treated patients achieving DAS28 remission increased from 42 to 67%. The estimated mean annual cost to treat a patient on b/tsDMARDs fell by 47%, from 13.1 thousand euros (EUR) in 2010 to 6.9 thousand EUR in 2019. The mean annual cost to treat b/tsDMARDs naïve patients was reduced by 75% (13.0 thousand EUR in 2010 and 3.2 thousand EUR in 2019). Conclusions In the period 2010–2019, b/tsDMARD treatment costs for Norwegian RA patients were significantly reduced, whereas DAS28 remission rates increased. Our data may indicate that the health authorities’ intention to reduce treatment costs by implementing a tender system has been successful.
dc.language.isoeng
dc.rightsThe Author(s)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleExploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs
dc.typeJournal article
dc.date.updated2022-01-11T06:03:18Z
dc.creator.authorBrkic, Alen
dc.creator.authorDiamantopoulos, Andreas P.
dc.creator.authorHaavardsholm, Espen A.
dc.creator.authorFevang, Bjørg T. S.
dc.creator.authorBrekke, Lene K.
dc.creator.authorLoli, Liz
dc.creator.authorZettel, Camilla
dc.creator.authorRødevand, Erik
dc.creator.authorBakland, Gunnstein
dc.creator.authorMielnik, Pawel
dc.creator.authorHaugeberg, Glenn
dc.identifier.doihttps://doi.org/10.1186/s12913-021-07425-w
dc.identifier.urnURN:NBN:no-92515
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/89915/1/12913_2021_Article_7425.pdf
dc.type.versionPublishedVersion
cristin.articleid48


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International